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Abstract
Viruses have evolved many mechanisms to invade host cells and establish successful infections. The interaction between viral 
attachment proteins and host cell receptors is the first and decisive step in establishing such infections, initiating virus entry 
into the host cells. Therefore, the identification of host receptors is fundamental in understanding pathogenesis and tissue 
tropism. Furthermore, receptor identification can inform the development of antivirals, vaccines, and diagnostic technologies, 
which have a substantial impact on human health. Nevertheless, due to the complex nature of virus entry, the redundancy in 
receptor usage, and the limitations in current identification methods, many host receptors remain elusive. Recent advances 
in targeted gene perturbation, high-throughput screening, and mass spectrometry have facilitated the discovery of virus 
receptors in recent years. In this review, we compare the current methods used within the field to identify virus receptors, 
focussing on genomic- and interactome-based approaches.
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Introduction
Viruses are intercellular pathogens dependent on their 
host’s cellular machinery for replication. To infect the host, 
the virus must first gain entry into the cell, breaching the 
cell’s primary barrier to infection, the cell membrane. The 
entry process is initiated by the interaction between viral 
attachment proteins and host cell surface structures. Host 
cell surface structures can act as either attachment factors, 
which localise the virus at the cell surface, or entry recep-
tors, which actively initiate virus entry (reviewed in [1]). 
In the literature, receptors are referred to as molecules that 
can mediate attachment, entry into the endocytic compart-
ment, entry from the endocytic membrane into the cytosol, 
and uncoating. Uncoating leads to the release of the viral 
genome from its protective capsid structure, and proceeds 
in a stepwise fashion under the guidance of cellular cues [2]. 
In this review, we use a narrower definition of a receptor, 
referring to those molecules that are actively involved in the 
entry of viruses into eukaryotic cells.
Interactions with host attachment factors are often elec-
trostatic and non-specific, only acting to localise the viral 
particle before the recruitment of specific receptors required 
for entry. Often, these are low-affinity interactions and utilise 
common glycolipids and glycoproteins found on host cells, 
such as heparan sulphate used by tick-borne encephalitis 
virus [3–5]. Additionally, viruses have been shown to use 
different attachment factors depending on the model system 
used, possibly reflecting wide host and tissue tropism [3].
After the virus is concentrated onto the host cells, bind-
ing to specific entry receptors can occur. These receptors 
actively facilitate host cell entry by one of two processes: 
receptor-mediated endocytosis or receptor-mediated activa-
tion of signalling pathways, leading to virus internalisation 
(reviewed in [6]). Some viruses only require one receptor to 
facilitate entry into host cells, such as sialic acid for influ-
enza A virus [7]. However, some viruses require co-recep-
tors on the same cell or different receptors on different cell 
types to initiate infection. This is observed for measles virus, 
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which uses the signalling lymphocyte-activation molecule 
and nectin-4 as receptors, and hepatitis C virus using tet-
raspanin, occludin, human scavenger receptor class B type 
I, and claudin-1 [8–13]. These receptors may be required 
for infection to occur, or partially redundant only assisting 
with viral infection. For hepatitis C, tetraspanin, occluding, 
and claudin-1 have been shown to be crucial for virus entry, 
whereas human scavenger receptor class B type I has been 
shown to be partially redundant [14].
Regardless of the method utilised by the virus for cell 
entry, virus–receptor interactions are pivotal in establishing 
infection. Therefore, understanding viral–receptor interac-
tions is of significant importance from a cell biology per-
spective, allowing us to expand our knowledge of viral life 
cycles, tissue and species tropism, and pathogenesis. Fur-
thermore, these insights can lead to the development of new 
antivirals, vaccines, and diagnostic technologies, combating 
pathogenic human viruses.
A wide range of methods have been applied over the years 
for the identification of viral receptors, with early studies 
(reviewed in [15]) using monoclonal and anti-idiotypic 
antibodies, solid-phase assays, and affinity purification 
with receptor antibodies [16–19]. However, over the last 
2 decades, the field has advanced significantly due to the 
development of targeted gene perturbation, high-throughput 
screening (HTS), and the application of a new generation of 
high-resolution orbital mass analysers [20]. This has led to 
techniques such as affinity purification mass spectrometry 
and genetic screening, becoming more common for receptor 
identification. In this review, we will compare and contrast 
different genomic and interactome approaches utilised for 
the identification of host protein receptors.
Genomic approaches
Genomic approaches have undergone significant advances 
over the past 2 decades, in particular through the evolution 
of HTS techniques. Genomic approaches can be divided into 
two categories: loss of function (LOF) or gain of function 
(GOF). LOF approaches inactivate host factors, allowing 
their influence on viral infections to be observed. In theory, 
genome-wide screening with this approach allows for the 
identification of all host factors, which either promote or 
inhibit infection. In contrast, GOF approaches introduce 
single new functionalities, from permissive cell lines into 
non-permissive ones. Virus entry can then occur if the 
GOF results in the expression of a functional receptor. In 
this review, we compare four gene perturbation techniques: 
complimentary DNA (cDNA), RNA interference (RNAi), 
random insertional mutagenesis, Clustered Regularly Inter-
spaced Short Palindromic Repeats/CRISPR associated pro-
tein 9 (CRISPR/Cas9) knockouts, activation (CRISPRa), and 
interference (CRISPRi). Currently, CRISPRa and CRISPRi 
have not been reported to our knowledge in any receptor 
identification reports, although CRISPRa has been used to 
identify viral host factors [21]. We consider that these two 
approaches, which have fewer off-target effects, will most 
likely be very useful in the future, but as such fall out of the 
scope of this review [22, 23]. CRISPR/Cas9 knockouts are 
discussed in the “Genetic Knockouts section”.
Genetic knockdowns
Genetic knockdowns can be produced using RNA interfer-
ence (RNAi) or CRISPR interference (CRISPRi). RNAi is 
a common approach utilised in LOF genetic screens and has 
been extensively reviewed [24–29]. RNAi acts to silence 
genes through the temporary removal of cellular mRNA, 
by RNA-induced silencing complexes (RISC) (Fig.  1) 
(reviewed in [30]). The RISC mechanism is universal, allow-
ing RNAi to be used in many cell lines.
There are three tools used to achieve RNAi: small inter-
fering RNAs (siRNAs), short hairpin RNAs (shRNAs), and 
long double-stranded RNAs (dsRNAs). However, the use 
of dsRNA is limited, as its presence induces the interferon 
response within vertebrate systems [31]. This causes cellu-
lar protein synthesis to close down, preventing specific loss 
of function phenotypes from being observed. Nevertheless, 
dsRNAs remain a good option for work within insect cell 
lines (reviewed in [32]). In 2011, a genome-wide dsRNAi 
screen within Drosophila cells identified nine transmem-
brane genes required for Sindbis virus infection [33]. Dros-
ophila natural resistance-associated macrophage protein 
(dNRAMP), the homologue of mammalian NRAMPs, was 
the only ubiquitously expressed, plasma membrane-associ-
ated protein identified. Molecular and biochemical assays 
demonstrated that dNRAMP yields a fivefold improve-
ment in virus attachment and is not required in processes 
downstream of entry, verifying its role as a virus receptor. 
Furthermore, mice deficient in NRAMP2 demonstrated a 
50-fold decrease in Sindbis virus infectivity, highlighting the 
potential of performing dsRNAi screens in Drosophila cells, 
to identify potential mammalian virus receptors.
In contrast to dsRNAs, both shRNAs and siRNAs can 
be used in mammalian systems. siRNAs are directly trans-
fected into cells and can be used in transient 3–7 day screens. 
Ephrin receptor A2 (EPhA2) was identified as an epithelial 
cell receptor for Epstein–Barr virus (EBV) using targeted 
siRNA screening [34]. Previously, it was reported that epi-
dermal growth factor increases EBV infectivity [35]. Pre-
treating cells with epidermal growth factor and monitor-
ing the transcription level in a microarray screen identified 
six upregulated genes. The initial hits were then probed 
using siRNAi and only EPhA2 knockdown was shown to 
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significantly decrease infectivity. The results were confirmed 
with three distinct siRNAs, thus excluding off-target effects. 
The results were then further validated using ectopic expres-
sion of complementary DNA, CRISPR/Cas9 knockdown, 
and co-immunoprecipitation assays. Finally, EPhA2 was 
determined to act as a receptor by monitoring the rate of 
virus internalisation in WT, EPhA2 knockdown, and EPhA2 
knockout cell lines.
shRNAs are delivered to the nucleus in a plasmid or 
lentivirus, and integrated into the host’s DNA, where they 
are then transcribed leading to the slow accumulation of 
shRNAs in the cytoplasm. Unlike siRNAs, shRNA expres-
sion is stable allowing for long-term screening (> 10 days). 
However, expression of shRNAs may be lost if the cells 
lose the plasmid, or if the lentivirus integration is silenced 
due to negative epigenetic regulation [36, 37]. Therefore, 
cells need to be cultured under selection for the shRNA 
phenotype. shRNAi has mainly been used to validate hits 
identified through other methods. shRNAi was performed 
on Bombyx mori embryonic cells to knockdown the cho-
lesterol transporter Niemann-Pick C1 (NPC1) [38]. NPC1 
was proposed as a potential baculovirus receptor, due to 
its interaction with Bombyx mori promoting protein which 
increases baculovirus production. Two unique shRNAs 
were used to target the NCP1 gene and a 40% reduction 
in NCP1 expression was achieved, leading to a substantial 
reduction in baculovirus infectivity. The receptor was then 
further validated by performing co-immunoprecipitation 
experiments with NCP1 and the major baculovirus gly-
coprotein, gp64. NCP1 was also identified as a potential 
receptor for Ebola virus, by genetic knockout screening in 
haploid cells [39]. This was validated by shRNA knock-
down of NPC1 in human peripheral blood monocyte-
derived dendritic cells, which yielded them resistant to 
filovirus infection.
A major issue with RNAi is a lack of reproducibility 
between similar studies [40–42] despite efforts to mini-
mise false positives [43, 44]. This has been investigated by 
directly testing the degree of overlap between two identical 
genomic screens. Hit lists containing 513 and 1140 hits 
were observed for two replicate screens, highlighting the 
impact of off-target effects, caused by both false-positive 
and false-negative results [45]. False positives occur due 
to the partial complementarity of siRNAs to multiple 
mRNAs throughout the ‘seed’ region (nucleotides 2–8 
of the 21 present in the siRNA sequence). When bind-
ing occurs through the seed region, this leads to transla-
tional repression and degradation of the mRNA, via the 
microRNA pathway leading to off-target effects [46]. False 
negatives can be generated by cytotoxic knockouts leading 
to cell apoptosis [47], functional redundancies caused by 
gene duplication preventing phenotypic manipulation by 
single gene knockdowns [48], variation in experimental 
conditions [49], and systematic errors [50].
Despite these limitations, RNAi is easy to use, has a fast 
knockdown of 24–48 h, and uses stable reagents, making it 
a good choice for generating loss of function phenotypes. 
Furthermore, as RNAi has a knockdown efficiency which 
is lower than 100%, this allows the study of essential 
genes, as the cells can survive, whilst the virus infection 
may be measurably inhibited. This is a major advantage 
over other loss of function gene perturbation methods, 
such as CRISPR/Cas9 or random insertional mutagenesis 
genetic knockouts, where permanent null phenotypes are 
generated.
Fig. 1  Schematic representation of RNAi silencing mechanism. For 
shRNA LOF screening, a lentiviral vector or plasmid encoding the 
shRNA (blue) is first integrated into the cellular DNA (green). The 
DNA is then transcribed by RNA polymerase III into shRNA and the 
shRNA exported into the cytoplasm by Exportin 5. For dsRNA and 
siRNA LOF screening, the interfering RNA is directly transfected 
into the cells. Both shRNAs and dsRNAs are processed in the cyto-
plasm by Dicer into siRNAs. The siRNAs are then loaded into the 
RISC and the passenger strand removed from the guide strand. The 
guide strand can then direct the RISC to the complementary mRNA 
target, where RISC cleaves the mRNA, leading to its degradation
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Genetic knockouts
Achieving complete genetic knockdowns using RNAi is 
difficult. To create true genetic knockouts, which dem-
onstrate a permanent homozygous null phenotype, del-
eterious gene mutations must be generated. True genetic 
knockouts can be generated using either random or site-
specific mutagenesis.
In random mutagenesis (reviewed in [51]), cells are, 
for example, transduced with a retroviral genetrap vec-
tor, containing a strong adenoviral splice acceptor site 
and a marker gene, such as green fluorescent protein. Fol-
lowing transduction, genetrap vectors are integrated into 
introns, leading to the production of truncated mRNAs 
[52]. The disrupted genes can then be identified, using 
the integrated DNA sequences as a molecular tag. Trans-
duction with genetrap vectors leads to biased insertion 
near active promoters, ensuring the generation of com-
plete knockouts [53]. The two main drawbacks are that it 
generates non-universal dispersed insertions, which may 
prevent all loci being targeted [54], and it is inefficient 
in diploid cell lines, where deleterious mutations must 
be generated in both chromosomes. This latter issue can 
be overcome through the use of haploid cell lines [55]. 
Screening using genetrap insertional mutagenesis, within 
haploid human cells (HAP1), identified receptors for both 
Ebola and adeno-associated virus serotype 2 (AAV2), [39, 
56]. In 2011, NCP1 was identified as a receptor for Ebola 
virus, accounting for 39 hits out of ~ 800,000 insertions. 
NCP1 was validated as a virus receptor by virus bind-
ing, replication and internalisation assays, and shRNA 
knockdown. In 2016, a library of mutagenized HAP1 cells 
containing almost all non-lethal knockouts was infected 
with AAV2 that expresses red fluorescent protein. Forty-
six significant hits were identified from cells resistant to 
infection. Of these hits, a previously uncharacterized type 
I transmembrane protein, KIAA0319L, showed the great-
est enrichment and was associated with 57 independent 
mutations. KIAA0319L was then confirmed as a receptor 
by generating CRISPR/Cas9 knockouts in eight different 
cell lines. All cell lines showed resistance to infection that 
was rescued through ectopic expression of KIAA0319L.
Site-specific mutagenesis can be performed using the 
CRISPR/Cas9 technology, which has the advantage that 
it equally targets all loci [57]. Although Cas9 is the most 
studied CRISPR associated protein, multiple CRISPR/
Cas subtypes exist within prokaryotic organisms [58]. 
The CRISPR/Cas9 system evolved as an adaptive immune 
system within bacteria and archaea, employing a trans-
acting CRISPR RNA: CRISPR RNA (tracrRNA:crRNA) 
duplex to target and destroy pathogenic DNA [59]. 
When performing genomic experiments, a fusion of the 
tracrRNA:crRNA duplex, known as a single-guide RNA 
(sgRNA) may be used. CRISPR/Cas9 knockouts are 
achieved through the generation of sgRNA targeted dou-
ble-stranded DNA breaks, which, following error-prone 
non-homologous end joining, lead to the generation of null 
phenotypes (Fig. 2: CRISPR/Cas9 Knockout) [60, 61]. In 
2019, receptors for both encephalomyocarditis virus and 
human cytomegalovirus (HMCV) were identified using 
genome-wide CRISPR/Cas9 screens with the GeCKOv2 
sgRNA library. The library targets 19,050 genes with 
six sgRNAs per gene [62–64]. To identify receptors spe-
cifically required for HMCV infection in epithelial cells, 
Xiaofei et al. performed parallel CRISPR/Cas9 screens in 
ARPE-19 epithelial cells and HEL fibroblasts [63]. The 
multipass membrane protein, OR14I1, was identified as 
an initial hit exclusive to the epithelial cell screen, and 
validated as a viral receptor by shRNA knockdown fol-
lowed by ectopic expression rescue, neutralisation, virus 
blocking and virus entry assays. Two identical CRISPR/
Cas9 screens within HeLa cells identified nine initial hits 
associated with encephalomyocarditis virus infection in 
replicate pools. A disintegrin and metalloproteinase nine 
domain (ADAM9) was the most significant hit with all 
six sgRNAs being significantly enriched. ADAM9 knock-
outs were also shown to be resistant to virus infection 
in both primary lung fibroblasts (pLF) from mice and 
HEK293T cells. ADAM9 was confirmed to function as 
an entry receptor through the use of RNA bypass assays. 
In addition, ADAM9 was independently identified as a 
receptor for encephalomyocarditis virus, using genetrap 
mutagenesis screening in haploid cells [65]. This shows 
that genetic knockout screening is a robust technique for 
receptor identification (Table 1). 
In contrast to RNAi, CRISPR/Cas9 knockouts have been 
shown to produce fewer false negative results [84]. Addition-
ally, CRISPR/Cas9 knockout screens have been developed 
within haploid cell lines, therefore increasing the reliability 
of generating gene disrupted phenotypes [85]. Due to tolerated 
mismatches at the sgRNA–target site interface, false positives 
also occur using CRISPR/Cas9 but at a 34% lower rate than 
with RNAi [86–88]. False positives can be reduced through 
the use of truncated sgRNAs (17–18 nucleotides compared 
to 20 nucleotides), which have a lower DNA-binding affinity 
and, therefore, are unable to tolerate mismatches in the target 
DNA [89]. Additionally, mutant CRISPR/Cas9 systems which 
require the correct localisation of two CRISPR/Cas9 mono-
mers to induce gene knockouts can also limit off-target effects. 
This approach is exemplified by CRISPR/Cas9 nickases, 
where the Cas9 molecule has been mutated to only introduce 
single-stranded DNA breaks, and therefore, two closely spaced 
CRISPR/Cas9 complexes are required to introduce staggered 
double-stranded DNA breaks (Fig. 2: CRISPR/Cas9 Nickase 
Knockout) [90]. As single-stranded nicks are repaired with 
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high fidelity by base excision repair, this minimises the genera-
tion of off-target gene depletions [91]. In another approach, the 
Cas9 nuclease activity has been removed and the endonucle-
ase domain of FokI fused to the Cas9. This mutant CRISPR/
Cas9 system can only induce double-stranded DNA breaks 
when two FokI endonuclease domains undergo dimerization, 
as FokI is not active in its monomeric form (Fig. 2: CRISPR/
Cas9 FokI Knockout) [92]. Although the utilisation of nick-
ases or Cas9 FOKI can reduce off-target effects, they also pos-
sess challenges for delivery with viral vectors, due to their 
increased nucleic-acid payload size. Therefore, the develop-
ment of higher fidelity variants of Cas9 through protein engi-
neering is favourable. Several such high fidelity Cas9s have 
now been developed including: SpCas9-HF1 [93], Sniper-
Cas9 [94], and eSpCas9 [95].
Ectopic expression of complementary DNA
In contrast to RNAi, random insertional mutagenesis, 
and CRISPR/Cas9 knockouts, cDNA libraries are used 
to introduce new functionalities into cell lines. cDNA 
libraries are synthesised from mRNA using reverse tran-
scriptases, before being cloned into plasmid or lentivi-
ral expression systems [96–98]. These libraries can then 
be utilised in GOF screening, whereby cDNA libraries 
developed from susceptible cell lines are transduced into 
non-susceptible cell lines, and retested for susceptibility. 
cDNA libraries have been used for receptor identification 
since the 1990s [9, 75, 76]. In 2018, a cDNA library con-
taining 8.4 × 106 primary clones derived from ARPE-19 
Fig. 2  Schematic representation of CRISPR/Cas9, CRISPR/Cas9 
nickase, and CRISPR/Cas9 FOKI genetic knockout mechanism. 
CRISPR/Cas9 genetic knockout: the CRISPR/Cas9 complex is first 
formed by combining an sgRNA and a Cas9 endonuclease. The 
sgRNA then guides the CRISPR/Cas9 complex to a specific region 
of the genomic DNA, and a double-stranded DNA break is induced 
by the Cas9 endonuclease. The double-stranded DNA break is then 
repaired non-homologously by the host cell, leading to the forma-
tion of insertions or deletions, which disrupt the open reading frame 
of the gene. CRISPR/Cas9 nickase genetic knockout: two CRISPR/
Cas9 nickase complexes are formed with two separated sgRNAs and 
mutated Cas9 nickase endonucleases. The sgRNAs then guide the 
CRISPR/Cas9 complexes to specific regions of the genomic DNA, 
and two single-stranded DNA breaks are induced by the Cas9 endo-
nucleases, forming a staggered double-stranded break. The double-
stranded DNA break is then repaired non-homologously by the host 
cell. CRISPR/Cas9 FOKI genetic knockout: Two CRISPR/Cas9 
FOKI complexes are formed with two separated sgRNAs and mutated 
dead Cas9 fused with the endonuclease FOKI. The sgRNAs then 
guide the CRISPR/Cas9 complexes to specific regions of the genomic 
DNA and the FOKI units dimerise. The FOKI dimer then induces a 
double-stranded DNA break which is repaired non-homologously
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epithelial cells was used to identify genes that promote 
HMCV entry [76]. HeLa cells which have a low HCMV 
infection rate of 1–5% were transfected with the cDNA 
library and infected with HMCV that expresses green 
fluorescent protein (GFP). Approximately 100 out of 1 
million clones showed an increase in green fluorescence, 
indicative of increased infectivity. DNA sequencing of 
the GFP expressing clones identified the cell surface mol-
ecule CD147 as a potential receptor. This was confirmed 
by shRNA knockdown, HMCV entry assays and co-locali-
sation immunofluorescence. GOF and LOF approaches are 
strongly complimentary, with cDNA rescue experiments 
acting as a major verification method for hits identified in 
RNAi screening (reviewed in [99]).
There are, however, several drawbacks to consider when 
using cDNA libraries for GOF screening. Firstly, it may be 
difficult to obtain a suitable non-susceptible cell line. Sec-
ond, non-susceptible cell lines must be genetically manipu-
lable. Third, the number of copies of each gene within the 
cDNA library is potentially biased by the abundance of 
mRNA in the susceptible cell line at the time of isolation. 
Therefore, receptors which have low expression levels may 
not be represented in cDNA libraries, preventing their iden-
tification. Fourth, cDNA libraries may contain truncated 
cDNA clones arising from early termination of reverse 
transcriptase activity. The inclusion of truncated cDNAs in 
the library can be prevented using high efficiency cloning 
methods which isolate full-length cDNAs using two dimen-
sional electrophoretic separation [100]. Finally, the reverse 
transcriptase step is error prone, and therefore, unwanted 
mutations within the cDNA library may lead to false nega-
tives [101].
Interactomics and proteomics
In contrast to the previously described genomic approaches, 
interactome and proteomics aim to directly identify the pro-
tein–protein interactions (PPIs), which occur between virus 
attachment proteins and their host receptors. Historically, 
Table 1  Examples of identified cellular receptors with the identification method used
Virus Identified receptor Identification method References
Sindbis virus NRAMP RNAi screening [33]
Epstein–Barr virus Ephrin receptor A2 RNAi screening [34]
Ebolavirus Niemann–Pick C1 Random insertional mutagenesis in Haploid 
cells
[39]
Adeno-associated virus (AAV) serotype 2 KIAA0319L Random insertional mutagenesis in Haploid 
cells
[56]
Lassa virus LAMP1 Random insertional mutagenesis in Haploid 
cells
[66]
Human-type A enteroviruses kremen1 Random insertional mutagenesis in Haploid 
cells
[67]
NRP2 Lujo virus Random insertional mutagenesis in Haploid 
cells
[68]
Encephalomyocarditis virus ADAM9 CRISPR/Cas9 screening [64]
Human cytomegalovirus OR14I1 CRISPR/Cas9 screening [63]
Norovirus CD300If CRISPR/Cas9 screening [69, 70]
Arthritogenic alphaviruses Mxra8 CRISPR/Cas9 screening [71]
Andes virus and Sin Nombre virus Protocadherin CRISPR/Cas9 screening [72]
Enterovirus B Neonatal Fc receptor CRISPR/Cas9 screening [73]
Bat influenza virus Human leukocyte antigen DR isotype CRISPR/Cas9 screening [74]
Hepatitis C virus Claudin-1 and occludin cDNA libraries [8, 10]
Bombyx mori nucleopolyhedrovirus SINAL10 cDNA libraries [75]
Human cytomegalovirus CD147 cDNA libraries [76]
Japanese encephalitis virus Hsp70 VOPBA [77]
Old World arenaviruses α-Dystroglycan VOPBA [78]
Human cytomegalovirus Nrp2 and PDGFRa Protein microarrays [79]
New world arenaviruses Transferrin receptor Affinity capture mass spectrometry [80]
Nipah virus Ephrin B2 Affinity capture mass spectrometry [81]
Japanese encephalitis virus PLVAP and GKN3 Affinity purification–mass spectrometry [82]
Vaccinina virus AXL, M6PR, DAG1, CSPG4 and CDH13 Cross-linked mass spectrometry [83]
Medical Microbiology and Immunology 
1 3
this has been performed using virus overlay protein bind-
ing assays (VOPBA) (reviewed in [102]). Although 
VOPBA have successfully identified receptors for several 
viruses, including lymphocytic choriomeningitis virus and 
lassa virus [78], VOPBA suffer from several problems. In 
VOPBA, all cellular proteins are subjected to gel electropho-
resis, transferred onto a membrane, and then probed with 
virus. Bands where virus–receptor interactions occur can 
then be visualised with antibodies, and the corresponding 
protein in a duplicate gel identified using mass spectrom-
etry. Failure to identify receptors can occur if the necessary 
three-dimensional conformation of the attachment domains 
or receptor complexes is destroyed by SDS-PAGE. Further-
more, it may not be possible to detect virus–receptor interac-
tions which have low binding affinities [103]. More recent 
methods remove the need for gel electrophoresis, instead 
probing virus–receptor interactions in more native environ-
ments, overcoming some of the issues present by VOPBA. 
Here, we will discuss the use of protein microarrays, affinity 
purification–mass spectrometry (AP–MS), and cross-linked 
mass spectrometry (XL-MS) for receptor identification.
Protein microarrays
Unlike VOPBA protein microarrays allow for the direct 
detection of PPIs without the requirement of SDS-PAGE. 
First, a protein microarray is generated by immobilising 
purified ‘bait’ proteins onto a glass slide. Next, the micro-
array is probed with virus, and the PPIs detected through 
the use of fluorescently-, enzymatically-, or radio-labelled 
recombinant proteins within the array, surface plasmon reso-
nance imaging, atomic force microscopy, electrochemical 
impedance spectroscopy, and mass spectrometry (reviewed 
in [104]).
The first functional protein array was developed by Zhu 
et al. in 2001 and used to determine substrate specificity 
within the yeast proteome [105]. Since then, many protein 
microarrays have been developed, including several com-
mercial microarrays (reviewed in [106]). Nevertheless, 
protein microarrays which target extracellular receptors 
remain few and far between. This can be partially attributed 
to the difficulties associated with the production of soluble 
transmembrane proteins. In 2007, Bushell et al. developed 
an avidity-based extracellular interaction screen (Avexis), 
where they recombinantly expressed the extracellular 
domains of transmembrane proteins, removing the insolu-
ble transmembrane region [107]. To identify low-affinity 
interactions, the proteins were additionally tagged with a 
coiled-coil sequence from the rat cartilage oligomeric matrix 
protein. This causes the pentamerization of the ‘bait’ pro-
teins and increases binding avidity.
In 2018, a high-throughput screening approach, based on 
Avexis was utilised for the identification of HMCV–receptor 
interactions [79]. A library containing the ectodomains of 
1297 human single transmembrane receptors was set up on 
an automated, cell independent platform. The library was 
then probed with the HMCV envelope glycoprotein pen-
tamer, gHgLpUL128-131A, and trimer, gHgLgO. Three hits 
were identified for the trimer: platelet-derived growth fac-
tor receptor A (PDGFRa), transforming growth factor beta 
receptor type 3 (TGFbRIII), and neuregulin2 (NRG2), and 
four hits for the pentamer: neuropilin-2 (Nrp2), thrombo-
modulin (THBD), the leukocyte immunoglobulin-like recep-
tor (LILRB3), and the immunoglobulin alpha Fc receptor 
(FCAR). The interactions were then probed using biolayer 
interferometry and surface plasmon resonance. No interac-
tion could be detected for NRG2 or FCAR, and only weak 
binding to LILRB3; therefore, these hits were excluded from 
further studies. The remaining potential receptors were then 
validated using competition assays with both recombinant 
protein and anti-receptor antibodies, lentiviral overexpres-
sion, and CRISPR/Cas9 knockdown. It was determined 
that only Nrp2 and PDGFRa acted as functional recep-
tors in vivo. Although THBD and TGFbRIII interact with 
HMCV in vitro, they were not shown to be essential for 
virus entry.
Although protein microarrays have the ability to detect 
PPIs in vitro, the detected interactions may not be biologi-
cally relevant in vivo. This is mainly due to difficulties asso-
ciated with producing recombinant proteins, which possess 
native post-translational modifications, such as glycans or 
disulphide bonds. Another limitation of protein microarrays 
is the cost and time requirements associated with generating 
large-scale libraries of recombinant proteins. A method to 
overcome this is the use of nucleic-acid programmable pro-
tein arrays (NAPPA), where DNA is directly deposited onto 
the microarray and the proteins are synthesised in situ using 
in vitro transcription and translation (IVTT) [108]. In 2016, 
a proof-of-concept study utilised IVTT and microfluidics 
to create an array of ~ 2100 proteins from ~ 2700 linear syn-
thetic genes [109]. The array was then probed with simian 
virus 40 (SV40) and 99 interactions were observed, includ-
ing 14 of the 22 positive controls. This demonstrates a high 
false-negative discovery rate of 36%. Finally, 25 hits were 
subjected to validation by co-immunoprecipitation, which 
confirmed 18 hits.
Affinity purification–mass spectrometry
AP–MS is one of the most common proteomic approaches 
used for the identification of virus–host interactions. 
The AP–MS, workflow is as follows: first, the host cells 
are infected with virus, allowing for the formation of 
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virus–receptor complexes. Following cell lysis, the com-
plexes are then isolated by affinity purification. Finally, the 
complexes can be identified and quantified using mass spec-
trometry (Fig. 3).
Often affinity capture with antibodies has been used to 
isolate virus–receptor complexes prior to analysis by mass 
spectrometry [110]. This requires a high affinity, specific 
antibody, preferentially recognising a conformational 
epitope of the virus capsid that is not hidden by receptor 
binding. Alternatively, affinity-tagged viruses can be used 
[111, 112]. This method enables binding partners against 
the affinity tag to be used in the affinity purification step. 
Therefore, tags can be chosen for which high affinity bind-
ing partners are readily available. To produce affinity-tagged 
virus, the virus either needs to be genetically tractable (e.g., 
through reverse genetics) to introduce the tag, or the affinity-
tagged protein is incorporated through in trans expression 
of the gene during virus infection. Again, the tag insertion 
should not sterically hinder receptor binding. Although not 
used to identify viral receptors, this approach has been used 
to identify virus–host interactions, involved in replication 
within dengue virus serotype 2 (DENV-2) [113]. Here, 
the full-length DENV-2 RNA genome containing a poly-
histidine and FLAG-tagged NS5 was synthesised in vitro 
using T7 RNA polymerase. Huh-7 cells were then infected 
with tagged-DENV-2, and the NS5 complexes isolated via 
FLAG pull-down 48 h post-infection, leading to the identifi-
cation of 97 interacting proteins. The most common AP–MS 
approach used in the identification of viral receptors is the 
use of individually tagged recombinant viral glycoproteins. 
The approach was used recently in 2018 to identify host 
cell receptors for Japanese encephalitis virus (JEV) [82]. 
Affinity purification was performed using plasma mem-
brane fractions of BALB/c mouse brain and the recombinant 
expressed, his-tagged, envelope protein of JEV, identifying 
42 interacting proteins. Hits were then analysed for mRNA 
upregulation during JEV infection and the envelope–host 
protein interactions studied in silico. Two hits, plasmalemma 
vesicle-associated protein and gastrokine three were then 
validated as viral receptors by overexpression using cDNA 
and knockdown using siRNAi. Although frequently used, 
this approach may not faithfully reproduce receptor-binding 
sites due to the exposure of surfaces that are hidden within 
virus assembly, therefore leading to the identification of false 
positives.
False positives can also occur during AP–MS experi-
ments due to the co-isolation of non-specifically bound pro-
teins. The presence of non-specifically bound proteins can 
partially be reduced through the use of tandem affinity puri-
fications [114]; where two different epitope tags are incor-
porated into the recombinant virus, and the virus–receptor 
complexes are purified in two consecutive affinity purifica-
tion steps.
Cross‑linking mass spectrometry
The interactions between viral attachment proteins and host 
receptors are intermolecular and transient; therefore, their 
direct detection within native environments is challenging. 
Cross-linking can overcome this, by introducing covalent 
linkages between the viral attachment protein and the host 
receptor. In the early 1970s, cross-linking was used in con-
junction with gel electrophoresis, to identify PPIs within 
ribosomes [115]. More recently, cross-linking has been com-
bined with high-resolution mass spectrometry (XL-MS), to 
identify PPIs and their physical interaction contacts [83].
During XL-MS, interacting proteins are covalently teth-
ered using chemical cross-linkers. Following cross-linking, 
the proteins are enzymatically digested, resulting in a com-
plex peptide mixture. This peptide mixture is then analysed 
using liquid chromatography–tandem mass spectrometry 
Fig. 3  AP–MS and XL-MS workflow comparison. AP–MS work-
flow: cells are first infected with the virus of interest, harvested, and 
lysed. The virus–receptor complexes are then isolated using affinity 
purification, and the purified proteins enzymatically digested and 
identified using LC–MS/MS and database searching. In XL-MS, the 
cells are also first infected with virus. However, a chemical cross-
linking reaction is then performed, before the harvesting and lysis of 
the host cells. Next, the proteins are enzymatically digested and iden-
tified using LC–MS/MS and database searching
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(LC–MS/MS) and the cross-linked peptides identified by 
comparing experimental MS/MS spectra, against a data-
base of computationally generated theoretical spectra. As 
the length of the cross-linkers is known, these can be used as 
distance constraints in order to perform structural modelling 
[reviewed in [116]].
There are numerous different types of cross-linkers 
available including: homobifunctional cross-linkers, heter-
obifunctional cross-linkers, zero-length cross-linkers, and 
trifunctional cross-linkers [reviewed in [117] ]. Trifunctional 
cross-linkers are particularly useful, as they allow for the 
introduction of additional functionalities, such as biotin 
handles, which can be used for affinity purification of the 
cross-linked species following protein digestion [83, 118]. 
Furthermore, trifunctional cross-linkers can also incorpo-
rate chemical cleavage sites to remove the biotin moiety fol-
lowing purification and an isotopically labelled spacer arm, 
which can be used for quantitation [119]. Frei et al. [120] 
performed a proof-of-concept study, whereby they identified 
seven cell surface proteins as potential virus receptors for 
mature vaccinia viruses, using a novel trifunctional chemo-
proteomic reagent (TRICEPS) in XL-MS. The TRICEPS 
reagent contains three functionalities: an NHS ester for 
coupling to ligands via primary amines; a trifluoroacetyl-
protected hydrazine that can bind glycoproteins on the cell 
surface following the introduction of aldehydes via mild 
oxidation, and a biotin group for affinity purification of 
the cross-linked products. To validate the hits, the proteins 
were subjected to siRNA knockdown and five proteins AXL, 
M6PR, DAG1, CSPG4, and CDH13 were shown to reduce 
virus infectivity by 40–60%. Furthermore, three of the pro-
teins identified: CSPG4, DAG1, and AXL had previously 
been identified as virus receptors or attachment factors using 
competition assays, mutagenesis studies, and co-localisation 
experiments [121–123]. Despite the success of this proof-of-
concept study, no further virus receptors have been identified 
using XL-MS. A possible cause for this is the complexity of 
data analysis associated with XL-MS (reviewed in [124]). 
MS/MS fragmentation is complicated for cross-linked pep-
tides, as the resulting peptide contains fragments from two 
proteins. This leads to a higher precursor charge state and a 
greater number of fragment ions. Furthermore, four types of 
cross-linked peptides can be present in the sample: dead-end 
cross-links, intrapeptide cross-links, interpeptide cross-links, 
and higher order cross-linked peptides. Consequently, to 
identify peptides, all possible peptide–peptide combinations 
need to be considered when performing database searches, 
drastically increasing the search space. Several specialised 
algorithms and software packages have been developed, 
which can aid in the identification of peptides (reviewed in 
[124]). We expect that such algorithm adaption will lead to 
more discoveries in the near future.
Practical considerations
Genetic screening approach
There are two types of screening approaches which can be 
adopted: pooled and arrayed, with each method possessing 
a unique set of advantages (Table 2). In pooled screening, 
a population of cells is either transduced with an RNA or 
cDNA library (RNAi, CRISPR/Cas9, and cDNA), or sub-
jected to retroviral gene trapping (haploid cell knockouts). 
The pooled cells then undergo selection for transduction or 
retroviral incorporation, and the populations are expanded. 
Following expansion, the cells are infected with the virus in 
question, and enrichment is performed either looking for a 
GOF or LOF that has an effect. Finally, hits are identified by 
next-generation sequencing [125–127].
In arrayed RNAi, CRISPR/Cas9, and cDNA screening, 
cells are also transduced with an RNA or cDNA library 
[128]. However, in contrast to pooled screening, a sin-
gle gene is targeted in each well, of a multi-well plate. In 
arrayed, random insertional mutagenesis screening, knock-
outs are first generated within low cell density pools; the 
Table 2  Advantages and disadvantages of pooled and arrayed genomic screening approaches
Pros Cons
Arrayed screening Can select a gradation of phenotypes
Rapid identification using library key
Short-term screening (less than 10 days)
Can be used for high-throughput screening
Custom-made libraries are available
For haploid cells, this requires long-term culturing and 
storage of numerous cell lines
Attached cells only
Expensive to purchase, use, and maintain libraries
Requires high-throughput plate reader or microscope for 
analysis
Pooled screening Simple setup
Does not require any specialised equipment
Can be used with suspension cells
Long-term screening (greater than 10 days)
Lower cost, particularly when performing survival 
screens
PCR/next-generation sequencing needed to identify hits
Cannot perform high-throughput screening
Requires high cell number
Requires a selection step
Limited number of readouts
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individual colonies are then picked and cultured in multi-
well plates [129]. Following knockdown or ectopic expres-
sion, the cells are infected with the virus in question, and 
the viral replication or cell number monitored for a GOF or 
LOF effect. Finally, hits are identified using the library key.
Choice of cell line, tissue, or animal model
Viruses demonstrate varying host ranges and tissue tropisms. 
Whether or not a cell is susceptible to infection is dependent 
on the expression of suitable entry receptors on the cell’s sur-
face. However, some viruses may utilise different receptors 
depending on the cell type, allowing them to be more promis-
cuous. Therefore, receptors identified within a specific haploid 
or diploid cell line, are not necessarily representative of all the 
receptors used by the virus, within all hosts, or all host tissues. 
This has been demonstrated for adenovirus serotype 5, where 
the coxsackievirus and adenovirus receptor (CAR) has been 
shown to act as the primary receptor in vitro. However, the 
vitamin K-dependent coagulation factor X (FX) acts as an 
alternative receptor within the human liver, bypassing CAR, 
and initiating infection [130, 131]. Furthermore, some viruses 
have been shown to adapt to cell culture conditions allowing 
them to utilise new receptors such as heparin sulphate [132]. 
The use of 3D cell models and animal models may lead to the 
identification of different receptors to those found in standard 
cell culture [133].
Conclusions
The study of virus–receptor interactions is crucial for the 
development of antiviral drugs, vaccines, and new diagnos-
tic technologies. Nevertheless, receptor identification has 
often been a laborious and time-consuming process. High-
throughput approaches now provide alternative, potentially 
faster methods for host receptor discovery, and have been 
used to identify numerous receptors within recent years 
(Table 1). In particular, genetic knockout screening has 
grown in popularity, leading to the discovery of several bona 
fide new receptors since 2017, including: NRP2 for Lujo 
Virus, protocadherin for Andes virus and Sin Nombre virus, 
kremen1 for multiple human-type A enteroviruses, neonatal 
Fc receptor for enterovirus B, and human leukocyte antigen 
DR isotype for bat influenza viruses [67, 68, 72–74].
Despite numerous elegant studies, our knowledge of entry 
receptors still remains limited. This can be linked to a series 
of experimental challenges including: the use of relevant cell 
lines, tissues or animal models; the production of suitable virus 
strains, genetic tractability, and the identification of interac-
tions in native environments (Tables 2, 3). Many of these meth-
ods result in multiple candidate molecules being identified and 
Table 3  Advantages and disadvantages of proteomic approaches
Pros Cons
Protein microarrays Several microarrays available commercially
Low avidity binding detected using ‘bait’ protein 
pentamerization
Quick generation of large-scale libraries using 
nucleic-acid programmable protein arrays
Several methods used to detect interactions
Detected interaction may not be biologically 
relevant in vivo
Difficult to produce recombinant proteins, with 
native post-translational modifications
Time-consuming and expensive to generate librar-
ies of recombinant proteins
High false-negative discovery rate in nucleic-acid 
programmable protein arrays
Affinity purification–mass spectrometry Affinity tagging allows the study of proteins 
where native antibodies are not available
Use of affinity tags that have high affinity antibod-
ies readily available
Library-independent method allows for true 
genome-wide high-throughput capability
Proteins purified in native form
Introduction of affinity tag requires a genetically 
tractable virus.
Affinity tag may interfere with virus function and 
protein folding
Cell lysis and affinity purification may prevent the 
detection of low avidity and transient interac-
tions.
False positives due to co-isolation of non-specifi-
cally bound proteins
Cross-linked mass spectrometry Identification of low avidity and transient interac-
tions
Enrichment and quantitation using trifunctional 
cross-linkers
Library-independent method allows for true 
genome-wide high-throughput capability
Can gain additional structural information about 
binding site
Requires specialised software to identify cross-
linked peptides
Requires the presence of residues susceptible to 
cross-linking on the surface of the virus and 
receptor
Detected proteins may not be functional receptors 
in vivo
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these need to be narrowed down in further validation stud-
ies. The choice of validation method depends on the initial 
identification method. Often orthogonal experiments are used, 
e.g., proteomic approaches are used to validate results from 
genomic approaches and vice versa. However, several other 
approaches can be used to validate virus receptors, such as, 
competition assays [134], small molecule inhibition of binding 
[135], co-localization immunofluorescence microscopy [39], 
and Förster resonance energy transfer assays [136].
In summary, receptor identification is seldom a straight-
forward process. Therefore, a one-method-fits-all approach 
cannot be adopted for receptor identification. More com-
monly, receptors are identified using a combination of dif-
ferent approaches, which contribute to the overall picture 
of virus entry.
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